Jim Coleman is not rich. At worse, his purchase means Cortex will not go belly up for over a year. While he can't trade on inside information, Stoll has mentioned he will try for a. an FDA meeting about CX717 vis-a-vis ADHD, and b. Cortex will meet with Organon towards the end of the year, so if anything happens within a narrow 90 day period, Coleman's purchase would not be construed as acting on insider information. The wild cards are 'out there.'
This purchase also means he is a believer. I find it to be a bullish signal.